{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:31Z","timestamp":1787021071884,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271973"],"award-info":[{"award-number":["82271973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91959118"],"award-info":[{"award-number":["91959118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The \u2018Five Five\u2019 Project of the Third Affiliated Hospital of Sun Yat-sen University","award":["2023WW103"],"award-info":[{"award-number":["2023WW103"]}]},{"name":"Guangdong Basic and Applied Research Foundation","award":["2021A1515010582"],"award-info":[{"award-number":["2021A1515010582"]}]},{"DOI":"10.13039\/501100015956","name":"Key Research and Development Program of Guangdong Province","doi-asserted-by":"crossref","award":["2019B020235002"],"award-info":[{"award-number":["2019B020235002"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China International Medical Foundation SKY Research Fund for Medical Imaging","award":["Z-2014-07-2101"],"award-info":[{"award-number":["Z-2014-07-2101"]}]},{"name":"China International Medical Foundation SKY Research Fund for Medical Imaging","award":["Z-2014-07-1912-15"],"award-info":[{"award-number":["Z-2014-07-1912-15"]}]},{"name":"Clinical Research Foundation of the 3rd Affiliated Hospital of Sun Yat-Sen University","award":["YHJH201901"],"award-info":[{"award-number":["YHJH201901"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gadobenate and gadoxetate are hepatobiliary magnetic resonance imaging (MRI) contrast agents. We intraindividually compared these two agents for the characterization of focal liver lesions (FLLs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 140 adult subjects were randomized to undergo two 3-T MRI exams separated by 7\u201314 days, one with 0.05\u2009mmol\/kg gadobenate and one with 0.025\u2009mmol\/kg gadoxetate. For both exams, we acquired the same unenhanced T1-weighted, T2-weighted, and diffusion-weighted sequences, followed by contrast-enhanced T1-weighted sequences during the dynamic and hepatobiliary phases (HBP) (at 20\u2009min for gadoxetate, at 120\u2009min for gadobenate). Three experienced unaffiliated readers independently evaluated each exam in blinded, randomized order for lesion nature (benign\/malignant) and specific lesion diagnosis. McNemar test, Wald tests. paired\n                      <jats:italic>t<\/jats:italic>\n                      -tests and \u03ba statistics were used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 208 FLLs (108 malignant and 100 benign) were confirmed at final diagnosis. Sensitivity and specificity for malignant\/benign differentiation ranged from 91.6% to 99.1% and from\u00a087.5% to 90.5% for gadobenate, and from\u00a086.0% to 91.6% and\u00a0from 79.7% to 83.6% for gadoxetate. Significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.025) higher values for gadobenate were determined for all diagnostic performance parameters except for sensitivity and negative predictive value for one reader. Significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) greater accuracy and confidence for specific lesion diagnosis was achieved with gadobenate for two of three blinded readers. Interreader agreement for malignant\/benign differentiation was better with gadobenate (\u03ba\u2009=\u20090.91\n                      <jats:italic>versus<\/jats:italic>\n                      \u03ba\u2009=\u20090.72).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gadobenate was superior to gadoxetate for the differentiation and diagnosis of malignant and benign FLLs for two of three readers. Further confirmatory studies that include a wider representation of different types of FLLs are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance statement<\/jats:title>\n                    <jats:p>Better diagnostic performance and greater confidence in the characterization of FLLs with gadobenate might improve patient management decisions and timings, and potentially lead to better patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Better diagnostic performance for the differentiation of FLLs was achieved with gadobenate for two of three readers.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Reader confidence for lesion diagnosis was greater with gadobenate.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Superior dynamic phase imaging with gadobenate was crucial for accurate lesion diagnosis.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s41747-025-00551-8","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:21:05Z","timestamp":1739884865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intraindividual crossover comparison of gadobenate dimeglumine-enhanced and gadoxetate disodium-enhanced MRI for characterizing focal liver lesions"],"prefix":"10.1186","volume":"9","author":[{"given":"Wenjie","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichi","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dailin","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid M.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-9579","authenticated-orcid":false,"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/hep.24679","volume":"54","author":"KJ Fowler","year":"2011","unstructured":"Fowler KJ, Brown JJ, Narra VR (2011) Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology 54:2227\u20132237. https:\/\/doi.org\/10.1002\/hep.24679","journal-title":"Hepatology"},{"key":"551_CR2","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1148\/rg.296095515","volume":"29","author":"MK Seale","year":"2009","unstructured":"Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29:1725\u20131748. https:\/\/doi.org\/10.1148\/rg.296095515","journal-title":"Radiographics"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1148\/rg.316115528","volume":"31","author":"MD Goodwin","year":"2011","unstructured":"Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31:1547\u20131568. https:\/\/doi.org\/10.1148\/rg.316115528","journal-title":"Radiographics"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00261-014-0227-5","volume":"40","author":"TA Hope","year":"2015","unstructured":"Hope TA, Fowler KJ, Sirlin CB et al (2015) Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 40:613\u2013625. https:\/\/doi.org\/10.1007\/s00261-014-0227-5","journal-title":"Abdom Imaging"},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"W490","DOI":"10.2214\/AJR.08.1732","volume":"193","author":"KW Doo","year":"2009","unstructured":"Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM (2009) Pseudo washout\u201d sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 193:W490\u2013496. https:\/\/doi.org\/10.2214\/AJR.08.1732","journal-title":"AJR Am J Roentgenol"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2214\/AJR.17.18981","volume":"210","author":"BC Allen","year":"2018","unstructured":"Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR (2018) Comparison of visualization rates of LI-RADS version 2014 major features with IV gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol 210:1266\u20131272. https:\/\/doi.org\/10.2214\/AJR.17.18981","journal-title":"AJR Am J Roentgenol"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00261-016-0726-7","volume":"41","author":"M Dioguardi Burgio","year":"2016","unstructured":"Dioguardi Burgio M, Picone D, Cabibbo G, Midiri M, Lagalla R, Brancatelli G (2016) MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine. Abdom Radiol (NY) 41:1546\u20131554. https:\/\/doi.org\/10.1007\/s00261-016-0726-7","journal-title":"Abdom Radiol (NY)"},{"key":"551_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/1178623X19827976","volume":"12","author":"CJ Zech","year":"2019","unstructured":"Zech CJ, Schwenke C, Endrikat J (2019) diagnostic efficacy and safety of gadoxetate disodium vs gadobenate dimeglumine in patients with known or suspected focal liver lesions: results of a clinical phase III study. Magn Reson Insights 12:1178623X19827976. https:\/\/doi.org\/10.1177\/1178623X19827976","journal-title":"Magn Reson Insights"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1007\/s00330-021-08068-5","volume":"31","author":"D Stocker","year":"2021","unstructured":"Stocker D, Hectors S, Bane O et al (2021) Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. Eur Radiol 31:9306\u20139315. https:\/\/doi.org\/10.1007\/s00330-021-08068-5","journal-title":"Eur Radiol"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1067\/j.cpradiol.2019.06.006","volume":"49","author":"F Vernuccio","year":"2020","unstructured":"Vernuccio F, Bruno A, Costanzo V et al (2020) Comparison of the enhancement pattern of hepatic hemangioma on magnetic resonance imaging performed with Gd-EOB-DTPA versus Gd-BOPTA. Curr Probl Diagn Radiol 49:398\u2013403. https:\/\/doi.org\/10.1067\/j.cpradiol.2019.06.006","journal-title":"Curr Probl Diagn Radiol"},{"key":"551_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jmri.22713","volume":"34","author":"A Frydrychowicz","year":"2011","unstructured":"Frydrychowicz A, Nagle SK, D\u2019Souza SL, Vigen KK, Reeder SB (2011) Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 Tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging; 34:585\u2013594. https:\/\/doi.org\/10.1002\/jmri.22713","journal-title":"J Magn Reson Imaging;"},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.ejrad.2011.10.014","volume":"81","author":"RT Gupta","year":"2012","unstructured":"Gupta RT, Marin D, Boll DT et al (2012) Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. Eur J Radiol 81:2457\u20132462. https:\/\/doi.org\/10.1016\/j.ejrad.2011.10.014","journal-title":"Eur J Radiol"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jmri.23874","volume":"37","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim BS, Kim MJ et al (2013) Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging 37:903\u2013908. https:\/\/doi.org\/10.1002\/jmri.23874","journal-title":"J Magn Reson Imaging"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5152\/dir.2019.18165","volume":"25","author":"A Taibbi","year":"2019","unstructured":"Taibbi A, Brancatelli G, Matranga D, Midiri M, Lagalla R, Bartolotta TV (2019) Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI. Diagn Interv Radiol 25:95\u2013101. https:\/\/doi.org\/10.5152\/dir.2019.18165","journal-title":"Diagn Interv Radiol"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/jmri.26227","volume":"49","author":"IJSML Vanhooymissen","year":"2019","unstructured":"Vanhooymissen IJSML, Thomeer MG, Braun LMM et al (2019) Intrapatient comparison of the hepatobiliary phase of Gd-BOPTA and Gd-EOB-DTPA in the differentiation of hepatocellular adenoma from focal nodular hyperplasia. J Magn Reson Imaging 49:700\u2013710. https:\/\/doi.org\/10.1002\/jmri.26227","journal-title":"J Magn Reson Imaging"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2214\/AJR.21.26818","volume":"218","author":"D Rong","year":"2022","unstructured":"Rong D, He B, Tang W et al (2022) Comparison of gadobenate-enhanced MRI and gadoxetate-enhanced MRI for hepatocellular carcinoma detection using LI-RADS version 2018: a prospective intraindividual randomized study. AJR Am J Roentgenol 218:687\u2013698. https:\/\/doi.org\/10.2214\/AJR.21.26818","journal-title":"AJR Am J Roentgenol"},{"key":"551_CR17","first-page":"709","volume":"62","author":"C Couinaud","year":"1954","unstructured":"Couinaud C (1954) Lobes et segments h\u00e9patiques: notes sur l\u2019architecture anatomiques et chirurgicale du foie [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver]. Presse Med 62:709\u2013712","journal-title":"Presse Med"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12029-010-9145-0","volume":"41","author":"L Grazioli","year":"2010","unstructured":"Grazioli L, Bondioni MP, Faccioli N et al (2010) Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine. Gastrointest Cancer 41:221\u2013232. https:\/\/doi.org\/10.1007\/s12029-010-9145-0","journal-title":"Gastrointest Cancer"},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/RLI.0b013e3181feee3a","volume":"46","author":"G Morana","year":"2011","unstructured":"Morana G, Grazioli L, Kirchin MA et al (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46:225\u2013239. https:\/\/doi.org\/10.1097\/RLI.0b013e3181feee3a","journal-title":"Invest Radiol"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmir.2010.09.003","volume":"41","author":"SD Chang","year":"2010","unstructured":"Chang SD, Stunell H (2010) A pictorial review of the MRI appearances of focal liver lesions. J Med Imaging Radiat Sci 41:180\u2013195. https:\/\/doi.org\/10.1016\/j.jmir.2010.09.003","journal-title":"J Med Imaging Radiat Sci"},{"key":"551_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13244-020-00928-w","volume":"12","author":"F Vernuccio","year":"2012","unstructured":"Vernuccio F, Gagliano DS, Cannella R, Ba-Ssalamah A, Tang A, Brancatelli G (2012) Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. Insights Imaging 12:8\u201324. https:\/\/doi.org\/10.1186\/s13244-020-00928-w","journal-title":"Insights Imaging"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/ajg.2014.213","volume":"109","author":"JA Marrero","year":"2014","unstructured":"Marrero JA, Ahn J, Reddy KR (2014) American college of gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 109:1328\u20131347. https:\/\/doi.org\/10.1038\/ajg.2014.213","journal-title":"Am J Gastroenterol"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med 22:276\u2013282","journal-title":"Biochem Med"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4254\/wjh.v10.i7.462","volume":"10","author":"R Inchingolo","year":"2018","unstructured":"Inchingolo R, Faletti R, Grazioli L et al (2018) MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol 10:462\u2013473. https:\/\/doi.org\/10.4254\/wjh.v10.i7.462","journal-title":"World J Hepatol"},{"key":"551_CR25","unstructured":"American College of Radiology (2022) Liver imaging reporting and data system. https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS\/CT-MRI-LI-RADS-v2018"},{"key":"551_CR26","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The Liver, European Organisation For Research And Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908\u2013943","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update Hepatology 53:1020\u20131022. https:\/\/doi.org\/10.1002\/hep.24199","journal-title":"Hepatology"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2214\/AJR.10.5113","volume":"196","author":"T Tamada","year":"2011","unstructured":"Tamada T, Ito K, Yamamoto A et al (2011) Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 196:824\u2013830. https:\/\/doi.org\/10.2214\/AJR.10.5113","journal-title":"AJR Am J Roentgenol"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2463\/mrms.2014-0125","volume":"15","author":"A Tateyama","year":"2016","unstructured":"Tateyama A, Fukukura Y, Takumi K, Shindo T, Kumagae Y, Nakamura F (2016) Hepatic hemangiomas: factors associated with pseudo washout sign on Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Med Sci 15:73\u201382. https:\/\/doi.org\/10.2463\/mrms.2014-0125","journal-title":"Magn Reson Med Sci"},{"key":"551_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1148\/radiology.203.1.9122423","volume":"203","author":"JM Lacomis","year":"1997","unstructured":"Lacomis JM, Baron RL, Oliver JH 3rd, Nalesnik MA, Federle MP (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203:98\u2013104. https:\/\/doi.org\/10.1148\/radiology.203.1.9122423","journal-title":"Radiology"},{"key":"551_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/hep.23600","volume":"51","author":"R Vilana","year":"2010","unstructured":"Vilana R, Forner A, Bianchi L et al (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51:2020\u20132029. https:\/\/doi.org\/10.1002\/hep.23600","journal-title":"Hepatology"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1148\/radiology.190.2.8284392","volume":"190","author":"B Hamm","year":"1994","unstructured":"Hamm B, Thoeni RF, Gould RG et al (1994) Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 190:417\u2013423. https:\/\/doi.org\/10.1148\/radiology.190.2.8284392","journal-title":"Radiology"},{"key":"551_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jmri.22241","volume":"32","author":"H Haradome","year":"2010","unstructured":"Haradome H, Grazioli L, Tsunoo M et al (2010) Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 32:334\u2013340. https:\/\/doi.org\/10.1002\/jmri.22241","journal-title":"J Magn Reson Imaging"},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1258\/ar.2012.120186","volume":"53","author":"C Schmid-Tannwald","year":"2012","unstructured":"Schmid-Tannwald C, Herrmann K, Oto A, Panteleon A, Reiser M, Zech C (2012) Optimization of the dynamic, Gd-EOB-DTPA-enhanced MRI of the liver: the effect of the injection rate. Acta Radiol 53:961\u2013965. https:\/\/doi.org\/10.1258\/ar.2012.120186","journal-title":"Acta Radiol"},{"key":"551_CR35","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1007\/s00330-019-06110-1","volume":"29","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yu X, Huo L et al (2019) Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI. Eur Radiol 29:5205\u20135216. https:\/\/doi.org\/10.1007\/s00330-019-06110-1","journal-title":"Eur Radiol"},{"key":"551_CR36","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.1007\/s00330-021-07807-y","volume":"31","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tang W, Xie S et al (2021) The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria. Eur Radiol 31:7715\u20137724. https:\/\/doi.org\/10.1007\/s00330-021-07807-y","journal-title":"Eur Radiol"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-025-00551-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-025-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:41:33Z","timestamp":1739925693000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurradiolexp.springeropen.com\/articles\/10.1186\/s41747-025-00551-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/s41747-025-00551-8","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethics Committee of the Third Affiliated Hospital of Sun Yat-Sen University (approval number: GH0255, dated: 25\/10\/2019) and all patients provided written informed consent to take part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}